or Try an Advanced Search...

    Technical Analysis for BDTX - Black Diamond Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 2.89 5.47% 0.15
    BDTX closed up 5.47 percent on Friday, November 1, 2024, on 30 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    Earnings due: Nov 4
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical BDTX trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Wide Bands Range Expansion 5.47%
    Oversold Stochastic Weakness 5.47%
    Slingshot Bearish Bearish Swing Setup 0.70%
    Wide Bands Range Expansion 0.70%
    Oversold Stochastic Weakness 0.70%
    Wide Bands Range Expansion 1.05%
    Down 3 Days in a Row Weakness 1.05%
    Down 4 Days in a Row Weakness 1.05%
    Older End-of-Day Signals for BDTX ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 18 hours ago
    Possible NR7 about 19 hours ago
    Possible Inside Day about 19 hours ago
    Up 5% about 22 hours ago
    60 Minute Opening Range Breakout about 23 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    BDTX Chart by TradingView
    Basic chart:

    Profile

    Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies for cancer treatment. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Cancer Treatment Enzymes Diamond Epidermal Growth Factor Receptor Tyrosine Kinase Receptors Genetic Diseases Oncogenes Therapies For Cancer Protein Kinase Rare Genetic Disease Rare Genetic Diseases Black Diamond Kinase

    Is BDTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 1 Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
    Oct 8 Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data
    Oct 7 Black Diamond CFO departs as part of restructuring, job cuts
    Oct 7 Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
    Sep 23 Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
    Sep 23 Black Diamond reports encouraging Phase 2 data for BDTX-1535
    Sep 23 Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
    Sep 22 Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
    Sep 14 Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
    Aug 22 Looking Into Black Diamond Therapeutic's Recent Short Interest
    See more BDTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 7.66
    52 Week Low 1.62
    Average Volume 1,385,284
    200-Day Moving Average 4.89
    50-Day Moving Average 4.41
    20-Day Moving Average 3.21
    10-Day Moving Average 2.99
    Average True Range 0.25
    RSI (14) 31.51
    ADX 40.5
    +DI 10.93
    -DI 28.28
    Chandelier Exit (Long, 3 ATRs) 3.23
    Chandelier Exit (Short, 3 ATRs) 3.49
    Upper Bollinger Bands 3.74
    Lower Bollinger Band 2.68
    Percent B (%b) 0.2
    BandWidth 33.18
    MACD Line -0.42
    MACD Signal Line -0.44
    MACD Histogram 0.0267
    Fundamentals Value
    Market Cap 149.23 Million
    Num Shares 51.6 Million
    EPS -2.13
    Price-to-Earnings (P/E) Ratio -1.36
    Price-to-Sales 0.00
    Price-to-Book 1.63
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 3.12
    Resistance 3 (R3) 3.10 3.01 3.08
    Resistance 2 (R2) 3.01 2.95 3.02 3.06
    Resistance 1 (R1) 2.95 2.92 2.98 2.97 3.05
    Pivot Point 2.86 2.86 2.88 2.87 2.86
    Support 1 (S1) 2.80 2.80 2.83 2.82 2.73
    Support 2 (S2) 2.71 2.77 2.72 2.72
    Support 3 (S3) 2.65 2.71 2.70
    Support 4 (S4) 2.67